|
|
|
|
|
|
|
|
|
02.08.26 - 23:12
|
CSL vs Telix shares: Which is the better buy? (Fool)
|
|
|
One valuation immediately caught my attention, while the other requires considerably more confidence in future growth.
The post CSL vs Telix shares: Which is the better buy? appeared first on The Motley Fool Australia....
|
|
|
|
|
|
|
21.07.26 - 23:03
|
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal (GlobeNewswire EN)
|
|
|
MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in Cancers, a peer-reviewed journal. The Phase 1 study evaluated TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix's first-in-class prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy candidate. The study's scientific purpose was to evaluate lesion concordance between 68Ga-PSMA-PET5 and multi-time point SPECT6 imaging for patient selection using a “theranostic” approach....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.07.26 - 01:12
|
Telix Pharmaceuticals: Q2 2026 revenue jumps 21% (Fool)
|
|
|
Telix Pharmaceuticals also provided an update on its key clinical pipeline and new partnerships.
The post Telix Pharmaceuticals: Q2 2026 revenue jumps 21% appeared first on The Motley Fool Australia....
|
|
|
20.07.26 - 23:03
|
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer (GlobeNewswire EN)
|
|
|
MELBOURNE (Australia) and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in the LUTEON study, the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC. LUTEON is a randomized, prospective, open label, multi-center study evaluating a CAIX-targeting radionuclide therapy in patients with relapsed or recurrent ccRCC....
|
|
|
16.07.26 - 12:12
|
Telix opens radiopharmaceutical facility in Australia for cancer treatment (PBR)
|
|
|
Known as Telix Manufacturing Solutions North Melbourne (TMSNM), the site is described as the country's first purpose-built facility to combine radiochemistry laboratories, clinical manufacturing, patient dose administration, and
The post Telix opens radiopharmaceutical facility in Australia for cancer treatment appeared first on Pharmaceutical Business review....
|
|
|
15.07.26 - 22:24
|
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer (GlobeNewswire EN)
|
|
|
MELBOURNE, Australia and INDIANAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and St Vincent's Hospital today announced that the first patients have been dosed with TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) in the OPTIMAL-e trial, led by Professor Louise Emmett for patients with metastatic hormone-sensitive prostate cancer (mHSPC) at St Vincent's Hospital in Sydney, Australia....
|
|
|
|
|
02.07.26 - 03:36
|
FDA Alignment to Advance ProstACT Global Phase 3 Trial (GlobeNewswire EN)
|
|
|
MELBOURNE, Australia and INDIANAPOLIS, July 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX, “Telix”) today announced the successful outcome of a Type B meeting with the United States (U.S.) Food and Drug Administration (FDA) to review the Part 1 safety and dosimetry data and Part 2 protocol design of the ProstACT Global Phase 3 trial of its therapeutic candidate TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in metastatic castration resistant prostate cancer....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
